Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy

Journal of Hypertension

Volumn 20, Issue 9, 2002, Pages 1855-1864

  Dahlof, Björn ^a   Zanchetti, Alberto ^a   Diez, Javier ^a   Nicholls, M Gary ^a   Yu, Cheuk Man ^a   Barrios, Vivencio ^a   Aurup, Peter ^a   Smith, Ronald D ^a   Johansson, Magnus ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atenolol; Atrial natriuretic peptides; Echocardiography; Hypertension; Left ventricular hypertrophy; Losartan; Neurohormones

Indexed keywords

ADRENALIN; ADRENOMEDULLIN; ALDOSTERONE; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; HYDROCHLOROTHIAZIDE; LOSARTAN; NORADRENALIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0036735588     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200209000-00032     Document Type: Article

References (47)

1. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
2. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
3. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy
4. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
5. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies
6. Discovery of losartan, the first angiotensin-II receptor antagonist
7. Overexpression of angioensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling
8. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice
9. Comparison of Ang-II with other growth-factors on ERG-1 and matrix gene-expression in cardiac fibroblasts
10. Angiotensin-II increases norepinephrine release from atria by acting on angiotensin subtype-1 receptors
11. Prevention of angiotensin-II-induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat
12. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: Role of blood pressure and endothelial function
13. Angiotensin-II increases vascular-permeability factor gene-expression by human vascular smooth-muscle cells
14. Regression of left ventricular hypertrophy with losartan potassium therapy in patients with hypertension
15. Effects of losartan on blood pressure and left ventricular mass in essential hypertension
16. Effects of losartan on hypertension and left ventricular mass: A long-term study
17. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
18. Effects of an angiotensin II receptor antagonist on urinary albumin excretion, left ventricular mass, and systolic and diastolic blood pressures in essential hypertension
19. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension - A double-blind randomized controlled study
20. Regression of left ventricular hypertrophy in human hypertension with irbesartan
21. Effects of an AT(1) receptor antagonist, an ACE-inhibitor and a calcium-channel antagonist on cardiac gene expressions in hypertensive rats
22. Cardiac-hypertrophy and brain natriuretic peptide in experimental-hypertension
23. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma
24. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study
25. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective randomized study evaluating regression of ventricular enlargement
26. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men
27. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure
28. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment
29. Adrenomudullin(1-52) measured in human plasma by radioimmunoassay: Plasma concentrations, adsorption, and storage
30. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man
31. A direct radioimmunoassay for aldosterone in plasma
32. Myocardial infarction with and without reperfusion in sheep: Early cardiac and neurohumoral infarction with and without reperfusion in sheep: Early cardiac and neurohumoral changes
33. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 Years of follow-up
34. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group
35. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: The LIVE study
36. Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: Relationships to 24 h blood pressure
37. Brain natriuretic peptide as a cardiac hormone in essential hypertension
38. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length
39. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype
40. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients
41. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization
42. Safety and tolerability of losartan potassium, and angiotensin-II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme-inhibitors for the treatment of systemic hypertension
43. Studies of the renal effects of angiotensin-II receptor blockade - The confounding factor of acute water loading on the action of vasoactive systems
44. Serum uric acid and cardiovascular events in successfully treated hypertensive patients
45. Hypertension and hyperuricemia